A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641) Meeting Abstract
| Authors: | Chi, K. N.; Rathkopf, D.; Attard, G.; Smith, M. R.; Efstathiou, E.; Olmos, D.; Small, E. J.; Lee, J. Y.; Sieber, P.; Dunshee, C.; Ricci, D.; Simon, J. S.; Zhao, X.; Kothari, N.; Cheng, S.; Sandhu, S. K. |
| Abstract Title: | A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641) |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-10-01 |
| Start Page: | mdz248.054 |
| Language: | English |
| ACCESSION: | WOS:000491295502324 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz248.054 |
| Notes: | Meeting Abstract: 897TiP -- Appears on page v354 of the abstract book -- Source: Wos |
